ACUTE MYELOID LEUKAEMIA WITH DOWN SYNDROME: A CASE SERIES ON THE USE OF
VINCRISTINE
Abstract
Myeloid Leukemia with Down Syndrome (ML-DS) is a unique entity of AML
with superior treatment response and overall survival compared to
children with AML. Despite all of it, ML-DS survival rates for children
in low- and middle-income countries (LMICs) remain poor. We described
three ML-DS cases, which were treated with vincristine, cytarabine and
daunorubicin plus triple intrathecal drugs. All of our three patients
successfully finished the treatment, with two patients were still
complete remission until now, and one died two days after finishing the
chemotherapy. ML-DS is treatable in our limited-resources setting in
Manado, Indonesia.